CLINICAL RESEARCH IN EMERGENCY MEDICINE
Professor Daniel Fatovich, Emergency physician and clinical researcher
Royal Perth Hospital Emergency Department &
Head of the Centre for Clinical Research in Emergency Medicine (CCREM)
Harry Perkins Institute of Medical Research &
Clinical Professor, UWA Medical School, Emergency Medicine
University of Western Australia, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | September 2025
Professor Daniel Fatovich is a senior emergency physician and clinical researcher at Royal Perth Hospital Emergency Department (ED), with over 30 years’ experience in the design and conduct of clinical research in Emergency Medicine. He is also Head of the Centre for Clinical Research in Emergency Medicine (CCREM) within the Harry Perkins Institute of Medical Research.
He is Professor of Emergency Medicine, University of Western Australia; Director of Research for East Metropolitan Health Service (EMHS), providing strategic advice and leadership; Board Member of the Royal Perth Hospital Research Foundation; Chair of the EMHS Research Advisory Committee.
Professor Fatovich was an inaugural executive member of the Australasian College for Emergency Medicine (ACEM) Research Committee (2019-2024) and the Clinical Trials Network (2018-2024) and has received over $33m in competitive grant funding.
In 2020 and 2023, he was Ministerial adviser for the passage of the Guardianship and Administration (Medical Research) Act Western Australia. In 2017-18, he was deputy chair of the WA Methamphetamine Taskforce. He is chief investigator for the Emerging Drugs Network of Australia (EDNA), which he describes as the most fabulous project of his career. This is best exemplified by a famous quote from Victor Hugo: there is nothing so powerful as an idea whose time has come. EDNA is a national toxico-surveillance system for detecting illicit, emerging and novel psychoactive substances, in presentations to sentinel Emergency Departments. In 2024, EDNA won a WA Health Excellence Award for Excellence in Research and Innovation, and the 2024 UWA Vice-Chancellor’s Award in Research Impact and Innovation.
Expertscape ranks him in the top 1% globally for expertise in Emergency Medicine. He loves to challenge doctors to think, and to think differently.
Source: Supplied
-
Visceral pain and the gut-brain axis
Professor Stuart Brierley is Director of the Visceral Pain Research Group, Director of the Hopwood Centre for Neurobiology, and Theme co-Leader of Lifelong Health at the South Australian Health and Medical Research Institute (SAHMRI).
Prof Brierley is an international expert on the ‘gut-brain axis’ and chronic visceral pain mechanisms. Current investigations are on a individual cell type called the enterochromaffin cell, and it helps signal pain and anxiety from the gastrointestinal tract to the brain.
-
Behavioural science in cancer screening, control and communication
Dr Dodd has an established international reputation as a behavioural scientist in cancer control and communication. Since completing her PhD in 2016, Dr Dodd has been awarded a three-year University of Sydney Postdoctoral Research Fellowship (2018-2021) and a three-year Research Fellowship at The Daffodil Centre (current). Dr Dodd is the co-chair of the ‘Strengthening and optimising approaches to cancer prevention, screening, and early detection’ hub at The Daffodil Centre (with more than 130 staff and students).
-
Radiation therapy techniques and combination treatments for sarcoma
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
As a radiation oncologist located in Sydney, Australia, Professor Hong is focused on treating patients with bone and soft tissue sarcoma. And as a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
